The impact of highly active antiretroviral treatment (HAART) on anti -human immunodeficiency virus (HIV) cytotoxic T lymphocytes (CTL) was studied in 17 patients with recent symptomatic HIV-1 primary infection receiving triple combination therapy. Anti-HIV CTL were initially detected in 15 patients. In 6, CTL disappeared rapidly and persistently after initiation of therapy. Most of them had a rapid and sustained decrease in plasma HIV RNA to undetectable levels. Conversely, in 6 other patients, CTL remained detectable, which was associated with a less efficient control of viral replication. In 3 others, CTL disappeared only transiently, without clear correlation with the virologic profile. Altogether, despite individual variations, there was a positive correlation between viral replication and anti -HIV-1 cytotoxicity in most subjects, suggesting that the persistence of viral antigens is the main determinant for the maintenance of CTL activity. This raises the question of the potential benefit of anti-HIV CTL induction by immunotherapy in acute seroconverters treated by HAART.
The early events in human immunodeficiency virus (HIV) this period [6] . Neutralizing antibodies are apparently not involved [6 -8] , but other mechanisms, such as antibody-depenprimary infection are critical determinants of the ultimate prodent cellular cytotoxicity, might be important [9] . NK cells gression toward AIDS, as indicated by the faster evolution of could also be involved in the control of viral replication in infection in symptomatic seroconverters than in asymptomatic the first few days after infection, but very little is known ones [1 -3] . The level of the initial peak of viral replication about this activity in primary infection. The CD8 T lymphocyte is not a reliable predictor of disease progression, while the responses are probably the major component of the immune plasma HIV RNA level becomes a good indicator of evolution response involved in controlling viral replication during pritoward AIDS at Ç6 months after infection, when an apparent mary infection. Both anti -HIV-1 cytotoxic T lymphocyte steady state of viral replication has been established [4, 5] .
(CTL) activity and inhibition of viral replication have been This suggests that the rate of progression toward AIDS in a detected early after infection and correlated with a decrease given individual results from early interactions between viral in plasma virus load [10 -14] . Furthermore, the recent observareplication and immunologic responses [3, 5, 6] . Antibodies tions of rapid selection of CTL-escaping virus early after infecmay contribute to the clearance of viruses from plasma during tion demonstrate that anti-HIV CTL exert a strong selective pressure on virus variants and are therefore probably efficient in lysing infected cells in vivo from the early phases of infec-JID 1998;178 (July) is only reliable for RNA levels ú50 copies/mL. Therefore, samples CTL activity may therefore be associated with a poor prognowith values õ50 copies/mL were considered undetectable.
sis (with high virus load) or with a good prognosis (with low
Generation of anti-HIV-1 polyclonal cell lines. Peripheral virus load) [20] . The qualitative nature of the CTL response blood mononuclear cells (PBMC) were isolated by density gradient must also be taken into account. The long-term persistence of centrifugation (Lymphocyte Separation Medium; Flow, Irvine, efficient CTL is likely to depend on the initial breadth of the UK) from freshly drawn heparinized venous blood. They were repertoire mobilized [5, 19 -21] and perhaps on less activation used after freezing and thawing. PBMC (10 6 /mL) were set up in of each CTL clone [19, 22] . culture with autologous phytohemagglutinin-activated lympho-Effective reduction of viral replication by drug treatment as cytes (2 1 10 5 /mL) prepared as described elsewhere [34] . The early as possible after infection could avoid the occurrence of cells were incubated for 3 days in RPMI 1640 supplemented with events critical for the development of HIV-1 -related pathogen-100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM L-glutamine, nonessential amino acids, 1 mM sodium pyruvate, 10 mM HEPES esis [23 -25] : the shift from non -syncytium-inducing to cytobuffer, and 10% heat-inactivated fetal calf serum and then mainpathogenic syncytium-inducing isolates, the appearance of imtained for 2-3 weeks at 10 6 /mL in medium supplemented with 10 mune and drug escape mutants, and the onset of chronic U/mL human recombinant interleukin-2 (Boehringer, Mannheim, immune activation, which could lead to the exhaustion of CTL Germany) before use as effector cells in the chromium-release test.
clones [5, 19, 26, 27] tion treated with lamivudine, zidovudine, and ritonavir.
The supernatants were then harvested, and the chromium released was measured in a gamma counter. The spontaneous release was 10%-20% of the total Cr incorporated. Specific chromium release
Materials and Methods
was calculated as 100 1 [(experimental release 0 spontaneous Subjects. Patients were enrolled into the Agence Nationale de release)/(total Cr incorporated 0 spontaneous release)]. HIV-spela Recherche sur le Sida 053 clinical trial of zidovudine, lamivucific cytotoxic activity was considered to be positive when the dine, and ritonavir combination in symptomatic primary HIV-1 specific chromium release was 10% higher than the values obtained infection. To be enrolled, patients had to present with at least two with wild type vaccinia virus for two different effector-to-target symptoms of acute primary infection within the 4 weeks before ratios. Cytotoxic activity was expressed in lytic units, calculated inclusion and to meet at least two of the following biologic criteria: for 10 8 effector cells, as 10 8 /(5000 1 E:T 30% ), where E:T 30% is the positive p24 antigenemia, no more than three bands on Western effector-to-target ratio that gives 30% specific lysis of 5000 target blot, negative or weakly positive ELISA test for HIV-1 at the time cells. E:T 30% was calculated by semilogarithmic interpolation of of inclusion. These subjects were given triple combination therapy, the curve giving the percentage of specific lysis as a function of consisting of zidovudine (500 mg/day), lamivudine (300 mg/day), the E:T ratio if statistically correct (R 2 ú .75). Values were considand ritonavir (1200 mg/day) [32] . Each subject was assigned a ered to be significant only when they were ú3.5. three-figure number as a code name (table 1). Day 0 refers to the start of treatment, which occurred 7-48 days after the onset of acute retroviral syndrome. Plasma HIV RNA and CD4 and CD8
Results
T cells were monitored on days 0, 3, 7, 14, and 28, monthly up to month 3-4, and then every 3 months (table 1) . Anti-HIV CTL CTL activity was detected before treatment in 15 of the 17 were tested on day 0 and at months 2, 4, 7, 12, and 18. seroconverters tested (figure 1). Various CTL specificities were HIV RNA measurement in plasma. Plasma was separated found, Env recognition being the predominant one (in 11 pawithin 2 h of blood sampling, aliquoted, and immediately stored tients), followed by Nef, Gag, and Pol (in 6, 6, and 3, respecat 080ЊC. HIV-1 RNA levels were measured by a quantitative tively). Seven patients recognized several proteins (3 patients reverse transcription-polymerase chain reaction assay (Amplicor reacted against two proteins and 4 against three proteins). Eight HIV-1 monitor; Roche Molecular Systems, Neuilly sur Seine, patients had CTL specific for only one protein (Env in 5 of France) [33] . The lower limit of detection for this assay was 200 them). No patient reacted against all four proteins tested. copies/mL. Samples with RNA levels õ200 copies/mL were ultra-In the 2 patients with no detectable cytotoxic activity at day centrifuged for a 10-fold concentration and retested by the Ultra 0, CTL remained undetectable throughout the study (patients Direct Assay, with a lower limit of quantification of 20 copies/ mL (Roche). However, the sensitivity of this Ultra Direct Assay 125 and 131). Both patients showed a dramatic decrease in / 9d4a$$jy03 05-06-98 13:15:33 jinfa UC: J Infect NOTE. Plasma HIV-1 RNA levels are expressed in copies/mL and are given at following time points: day 0 (D0) and months 4, 7, 9, 12, and 15 (M4, M7, M9, M12, and M15); -indicates undetectable plasma HIV RNA levels (õ50 copies/mL). Time of undetectability is first day of undetectability of plasma HIV RNA; duration of undetectability is interval in days between first time of undetectability and subsequent first time of reappearance of HIV RNA in plasma if ever. Delay between first appearance of symptoms of HIV-1 primary infection and initiation of treatment (in days). Deviations from strict compliance with triple combination therapy are indicated with symbols below: * Poor observance of treatment. † Interruption of antiprotease, strict observance of double combination therapy. ‡ Interruption of treatment or patient lost to follow-up (Lost).
plasma HIV RNA to persistently undetectable levels from in 3 of the 4 patients tested, as illustrated with patient 137 in figure 2. Thus, even large doses of stimulating viruses failed month 6 and month 2 onwards, respectively (table 1) .
Early and persistent disappearance of anti-HIV CTL was to produce any anti-HIV CTL activity from PBMC samples obtained after several months of efficient treatment. Con-observed in 6 patients (patients 116, 134, 138, 144, 127, and 137; figure 1) in the course of antiretroviral tritherapy. They versely, the CTL response observed with PBMC taken on month 2, when viremia was clearly detectable, could be effi-were undetectable as early as at the first point of follow-up (month 2) in 4 patients (138, 116, 134, and 144) and by month ciently restimulated by autologous cells taken on month 4, when the plasma HIV RNA was dramatically reduced to õ200 4 in the remaining 2 (137 and 127). In all of these patients, CTL remained undetectable throughout the observation period, copies/mL. On the whole, these results strongly suggest that there is a drastic decrease or even a lack of memory CTL in up to 18 months after initiation of treatment.
The median initial virus load of these 6 patients was 244,375 these patients who had a rapid decrease in viral replication to undetectable levels. copies/mL (range, 6650 -879,540) (table 1). By month 4, plasma HIV RNA was undetectable in 2 of these 6 patients In 6 other patients (112, 114, 115, 119, 132, and 124), anti-HIV CTL were constantly detectable during the study period (116 and 134) and had decreased to between 50 and 200 copies/ mL in the remaining 4 (median, 99; range, 56 -161). Thereafter, (figure 1). However, some fluctuations were observed in the CTL response, both quantitatively and qualitatively. In patients HIV RNA plasma levels further decreased below the 50-copy threshold and remained undetectable until the end of follow-114 and 119, the intensity of the anti-HIV cytotoxic activity decreased in the course of treatment, with disappearance of the up in these 6 patients.
Since plasma HIV RNA became rapidly undetectable in most reactivity against Nef in patient 119. Conversely, in patient 115, both the intensity and the breadth of the anti-HIV cytotoxic of these patients, the lack of detectable CTL observed in the evolution could have been due to insufficient amount of virus activity tended to increase over time, with appearance of CTL directed against Pol and Env after 2 months and 1 year of for in vitro restimulation of autologous cells. Therefore, we looked for CTL activity by cultivating PBMC sampled at treatment, respectively (figure 1). Significant CTL activity has constantly been observed in patient 124, although the specifici-months 4 or 7, when no CTL were found, with, as stimulators, their autologous cells taken on day 0 when viremia was at its ties recognized had changed: Env-specific CTL were detected initially (day 0) and disappeared later, whereas Gag-specific maximum. This did not change the pattern of CTL responses CTL appeared on month 2 and were always found afterwards.
Plasma viral RNA has been almost always detectable in these 6 patients (table 1) . However, individual variations were We confirmed by CD8 and CD4 T cell depletion that both anti-Env and anti-Gag CTL were CD8 T cells. In addition, we could also observed in the virologic profile: in 2 patients (114, 119), HIV RNA plasma levels had been consistently high above not detect anti-Env activity in cultures of PBMC sampled at month 7 stimulated by autologous cells sampled at day 0, which threshold until 1 year after initiation of therapy; in 2 other patients (124 and 132), virus load decreased to undetectable suggests once again the loss of anti-Env memory CTL.
/ 9d4a$$jy03
05-06-98 13:15:33 jinfa UC: J Infect month 2, when plasma HIV RNA was decreased to Ç200 copies/mL. At month 7, the CTL activity reappeared but only directed against Gag. An increase in HIV RNA plasma levels was also observed, concurrent with the withdrawal of ritonavir because of side effects. A nearly similar pattern of CTL evolution was observed in patient 139, but with a complete switch in specificity: actually the anti-Nef CTL detected initially disappeared, while CTL specific for Gag were detected at month 12 (figure 1). However, his virologic profile was completely different from that of patient 104, since plasma HIV RNA levels had become and remained undetectable from month 2 up to the end of follow-up, at month 15.
Discussion
Cytotoxic lymphocytes were found in 15 of the 17 patients tested during acute primary infection. Such an early activity has been already described [10 -13, 35] . The frequency of response is somewhat higher than that reported in a large series of recently infected persons [35] . However, this work describes cytotoxic CD4 and CD8 effector cells expressing lysis of HIVspecific targets without any in vitro stimulation. The protocol that we used allows the detection of CD8 memory CTL, and the different technical approaches may explain the observed differences. The predominant recognition of Env has been pre-levels at month 2 and 7, respectively, but rebounded after a short period. It is noteworthy that in all 4 patients, the less viously reported, but other proteins are frequently recognized, as currently observed later in HIV infection, and as we have efficient control of viral replication appears correlated with a poor compliance with therapy. This is particularly the case for previously reported in untreated persons during primary infection [10] . The 2 patients who did not have any CTL activity patients 124 and 132, who transiently interrupted their treatment around month 7 and 4, respectively (table 1) . Indeed, before treatment were not different from the 15 responders in terms of virus load or delay between the onset of first symptoms patient 124 was lost to follow-up at month 9. The 2 remaining patients (112 and 115) appeared to have a better control of the and the first blood sampling (table 1) . Cytotoxic activity remained negative in the 2 patients in virus load. Both were compliant with therapy (table 1). As soon as month 1, HIV RNA plasma levels of patient 112 were which it was lacking at time of inclusion. In these patients, HIV-1 RNA had become undetectable from month 7 and month õ200 copies and remained so throughout the study period except at one time point (month 4). However, most of the 9 onward (table 1). In the course of treatment, CTL activity disappeared in 6 plasma samples of patient 112 were quantitated above 50 copies/mL of HIV RNA by the Ultra Direct Assay, suggesting the patients who did initially respond. This disappearance occurred early, and CTL remained undetectable. Conversely, CTL were persistence of a low but continuous ongoing viral replication. In patient 115, the virus load became undetectable by month constantly detectable in 6 other patients. In 2 additional patients, CTL disappeared at the first two time points during 9 and has remained so thereafter. However, the decrease was only slowly progressive, with values ú1000 copies/mL up to follow-up and reappeared later, while in the last patient, CTL persisted with a declining activity, to disappear completely at month 4.
In the last 3 patients, we observed a transient disappearance a single time point and reappear thereafter. Neither the initial virus load nor the delay between the onset of CTL activity (patients 129, 104, and 139; figure 1 ). In patient 129, the reactivity against Pol disappeared at month 2, while of acute retroviral syndrome and the initiation of treatment were correlated with the maintenance or the loss of CTL activ-that against Gag progressively decreased, with complete disappearance at month 7. However, CTL directed against both pro-ity (table 1) . Neither was there a clear correlation between T lymphocyte counts and virus load or CTL activity. Neverthe-teins reappeared at month 12. In this patient, plasma HIV RNA remained clearly detectable, ú200 copies/mL, for the whole less, most patients had a moderate to high increase in CD4:CD8 ratio, beyond 1 when plasma HIV RNA levels decreased to period of observation (except at month 12). In patients 104 and 139, anti-HIV CTL activity was undetectable at two con-õ200 copies/mL. The normalization of the CD4:CD8 ratio after treatment with a combination of three reverse transcriptase secutive time points but reappeared thereafter. In patient 104, the CTL directed against Env, Gag, and Nef disappeared at inhibitors was also reported recently in seroconverters [ was not observed in subjects treated later in the course of HIV patients 112 and 139 presented with persistently low virus loads and yet maintained CTL activity. Similarly, in patients 119 and infection [36] .
Our results suggest that a critical factor associated with sus-124, the initial control of the virus load was identical in kinetics to that observed in those who lost their CTL activity (figure tained disappearance of anti-HIV CTL is the efficiency of control of viral replication. Indeed, by month 4, plasma HIV RNA 1), but CTL activity was constantly observed. We verified and confirmed by Heteroduplex Mobility Assay that these patients levels were drastically decreased to õ200 copies/mL in the 6 patients in whom CTL activity disappeared completely and were infected with virus belonging to clade B, so their virus load was not underestimated by the Amplicor HIV-1 monitor even to õ50 copies/mL in subjects 116 and 134 (table 1) . Furthermore, all 6 patients had a sustained control of viral test, which has been shown to recognize poorly some HIV clades [37] . replication, since none showed reappearance of virus in plasma for the whole period of observation. Conversely, viral replica-
The profile of patient 112 appears particularly interesting. This patient was initially considered as a good responder to tion appeared less controlled in most patients who maintained CTL activity (table 1) . This is particularly the case for 4 of therapy, since his virus load had become undetectable early in therapy (õ200 copies/mL), from month 2 up to the end of them (114, 119, 124, 132) . Compliance with therapy appears a key factor for the control of virus load. Indeed, compliance follow-up, which was consistent with good compliance. However, when his samples were quantitated with the Ultra Direct was achieved in the 6 patients who showed disappearance of CTL activity but not in 4 of the 6 patients with persistently Assay, HIV RNA was almost always detected at low levels slightly above 50 copies/mL. This suggests low but ongoing detectable CTL (114, 119, 124, 132). In patients 124 and 132, the rebound of the virus load following cessation of therapy viral replication in this patient. This is further strengthened by a persistent high provirus load, in contrast to patients 134 and after an initial decrease of HIV RNA plasma levels further strengthens this point. 125, as assessed by HIV intracellular DNA analysis (data not shown). This virologic profile may explain the persistence of However, on an individual basis, the patterns of virologic and immunologic profiles may vary substantially. For instance, the CTL activity in this subject. The maintenance of sustained / 9d4a$$jy03 05-06-98 13:15:33 jinfa UC: J Infect viral replication in lymphoid organs or other cryptic sites [38, probably too simplistic. A subtle balance should exist between viral replication and CTL responses. In consequence, the lack 39] may also account for sustained anti-HIV cytotoxic activity despite very low or undetectable plasma viremia. Indeed, a of CTL activity may be associated either with a poor prognosis (with high virus load) or with a good prognosis (with low virus significant heterogeneity in the response of lymphoid organs to a 6-month period of antiretroviral therapy has been recently load) [20] . An important question to be addressed by future studies is reported, even when ú99.9% of virus was cleared in most patients [31] . The presence of anti-HIV CTL without detectable whether the down-regulation of HIV-specific CTL induced by HAART during primary infection could have any consequence plasma HIV RNA could then be an indicator of less efficient control of viral replication in the lymphoid organs. The clear-for future evolution. The absence of any detectable CTL, even in response to large doses of stimulating viruses, suggests that most ance of virus from lymphoid organs remains the main goal to achieve, and this question appears currently critical. The fol-patients in whom CTL activity decreased actually lack memory CTL. This abrogation of anti-HIV memory CTL could be prob-low-up of patients with particular virologic and immunologic profiles, and especially their virologic and immunologic evalua-lematic in case of cessation of therapy or escape of virus from antiretroviral drugs, since these patients will have to mount a new tion at the lymphoid tissue level, would therefore be of great interest to further analyze this point.
anti-HIV immune response as in a de novo infection. However, the reappearance of Gag-specific CTL in patient 104, when the Patients 144 and 115 have apparent similar virologic profiles. However, CTL activity disappeared in the former and remained cessation of ritonavir led to an increase in virus load, may indicate the existence of CTL memory in this subject. In fact, the reappear-detectable in the latter. As previously discussed, a difference in virus load within their lymphoid organs may account for ance of CTL from memory CTL, or the induction of new effectors, cannot be proven in such experiments, and only analysis of the this discrepancy. However, their virologic profiles are identical only in terms of kinetics. Indeed, the virus load of patient 115 optimal epitopes recognized or T cell receptor CDR3 sequencing could clarify this point. Evolution in patients 124 and 139 argues was always greater than that of patient 144, with a ú1-log difference at each time point from day 3 after treatment up to in favor of emergence of new CTL populations after a transient CTL disappearance. month 4. This delayed response to therapy with a slow rate of decrease in HIV RNA levels may also be responsible for the It is noteworthy that anti-HIV CTL never completely disappeared from patients at later stages of HIV infection who were persistence of CTL activity.
The relationship between virus load and CTL activity ap-undergoing antiretroviral triple therapy, even in those with decrease of plasma HIV RNA to õ200 copies/mL (unpublished pears more complex in 2 of the 3 patients who displayed a transient disappearance of CTL activity. In patient 104, the data). These differences in the evolution of the CTL response to triple therapy depending on the stage at which treatment is initiated anti-HIV CTL activity and the plasma HIV RNA levels evolved in close parallel: anti-HIV CTL disappeared at month 2 and 4 may result from different parameters. The duration and the intensity of CTL stimulation by active viral replication may be an when HIV plasma RNA levels were at their lower values, õ200 copies/mL, and anti-Gag CTL reappeared concurrently with the important factor for the maintenance of memory cells, as already suggested for subject 115. The amount of intracellular RNA, increase in plasma HIV RNA levels when this patient stopped ritonavir. By contrast, the evolution of virus loads did not intracellular proviral DNA, and the virus load within the lymphoid organs are other factors that may vary in different ways under parallel that of CTL activity in the 2 other patients. Patient 129 maintained significant levels of HIV RNA in plasma when therapy according to the stage of infection. The understanding of the mechanisms underlying the maintenance or the disappearance CTL activity disappeared transiently. In patient 139, the initial response was directed only against the Nef protein. This re-of memory CTL after therapy at different stages of the disease clearly requires further investigation. sponse completely disappeared, while a Gag-specific response appeared much later in the evolution, even though the plasma These results also raise the question of the potential benefit of an additional immunotherapy in patients with efficient reduc-HIV RNA had been undetectable for 9 months.
In summary, although individual patterns may be observed, tion of plasma HIV RNA in the course of antiretroviral triple combination therapy. The appearance of HIV-specific T helper there was a good correlation between the sustained decrease in plasma HIV RNA to undetectable levels and the disappear-activities has been recently reported in seroconverters receiving HAART [42], and we have observed a similar phenomenon in ance of CTL activity. These results suggest that a certain amount of virus production is required to maintain CTL activ-another cohort of patients during primary infection (data not shown). These HIV-specific CD4 T lymphocytes would be of ity, as already described in asymptomatic patients with high CD4 T cell counts, low virus loads, and no detectable CTL importance for efficient reactivation or de novo induction of anti-HIV CTL by immunization [42] . It is interesting to note, [30, 40, 41] . It is noteworthy that some of these asymptomatic patients further developed anti-HIV cytotoxic responses during however, that the appearance of HIV-specific CD4 helper T cells does not seem to be sufficient to sustain a strong CTL evolution when virus burdens increased [40, 41] . Therefore, the view that CTL activity controls HIV-1 replication, and that response when the antigenic mass has already drastically diminished. a lack of CTL is associated with increased virus burden, is 
